ENLV
Enlivex Therapeutics Ltd.NASDAQHealthcare$0.95-8.24%ClosedMarket Cap: $23.1M
As of 2026-04-06
Valuation
P/E (TTM)
0.02
PEG
0.00
P/B
0.02
P/S
0.00
EV/EBITDA
-1.39
DCF Value
$-0.04
FCF Yield
-52.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
248.1%
ROA
53.1%
ROIC
-0.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-5.9M | $1.24B | $25.79 | — |
| FY 2025 | $0.00 | -Infinity% | $-15.0M | $1.24B | $25.48 | — |
| Q3 2025 | $0.00 | -Infinity% | $-2.6M | $-2.2M | $-0.09 | — |
| Q2 2025 | $0.00 | -Infinity% | $-3.1M | $-1.9M | $-0.08 | — |
| Q1 2025 | $0.00 | -Infinity% | $-3.5M | $-3.5M | $-0.16 | — |
| Q4 2024 | $0.00 | -Infinity% | $-5.6M | $-5.2M | $-0.24 | — |
| FY 2024 | $0.00 | -Infinity% | $-15.5M | $-15.0M | $-0.73 | — |
| Q3 2024 | $0.00 | -Infinity% | $-3.1M | $-2.6M | $-0.12 | — |
| Q2 2024 | $0.00 | -Infinity% | $-3.0M | $-3.1M | $-0.16 | — |
| Q1 2024 | $0.00 | -Infinity% | $-4.0M | $-4.1M | $-0.22 | — |
| Q4 2023 | $0.00 | -Infinity% | $-6.1M | $-9.1M | $-0.49 | — |
| FY 2023 | $0.00 | -Infinity% | $-29.4M | $-29.1M | $-1.56 | — |